Silverfin false false 31/03/2024 01/04/2023 31/03/2024 Dr Ankur Chopra 29/03/2022 Robyn Alexandra Chopra 29/03/2022 25 March 2025 The principal activity of the company during the financial year was that of medical practice activities. 14008998 2024-03-31 14008998 bus:Director1 2024-03-31 14008998 bus:Director2 2024-03-31 14008998 2023-03-31 14008998 core:CurrentFinancialInstruments 2024-03-31 14008998 core:CurrentFinancialInstruments 2023-03-31 14008998 core:Non-currentFinancialInstruments 2024-03-31 14008998 core:Non-currentFinancialInstruments 2023-03-31 14008998 core:ShareCapital 2024-03-31 14008998 core:ShareCapital 2023-03-31 14008998 core:RetainedEarningsAccumulatedLosses 2024-03-31 14008998 core:RetainedEarningsAccumulatedLosses 2023-03-31 14008998 core:LandBuildings 2023-03-31 14008998 core:Vehicles 2023-03-31 14008998 core:ToolsEquipment 2023-03-31 14008998 core:LandBuildings 2024-03-31 14008998 core:Vehicles 2024-03-31 14008998 core:ToolsEquipment 2024-03-31 14008998 2022-03-28 14008998 bus:OrdinaryShareClass1 2024-03-31 14008998 2023-04-01 2024-03-31 14008998 bus:FilletedAccounts 2023-04-01 2024-03-31 14008998 bus:SmallEntities 2023-04-01 2024-03-31 14008998 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 14008998 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 14008998 bus:Director1 2023-04-01 2024-03-31 14008998 bus:Director2 2023-04-01 2024-03-31 14008998 core:LandBuildings 2023-04-01 2024-03-31 14008998 core:Vehicles core:TopRangeValue 2023-04-01 2024-03-31 14008998 core:ToolsEquipment 2023-04-01 2024-03-31 14008998 2022-03-29 2023-03-31 14008998 core:Vehicles 2023-04-01 2024-03-31 14008998 core:Non-currentFinancialInstruments 2023-04-01 2024-03-31 14008998 bus:OrdinaryShareClass1 2023-04-01 2024-03-31 14008998 bus:OrdinaryShareClass1 2022-03-29 2023-03-31 iso4217:GBP xbrli:pure xbrli:shares

Company No: 14008998 (England and Wales)

DR CHOPRA LTD

Unaudited Financial Statements
For the financial year ended 31 March 2024
Pages for filing with the registrar

DR CHOPRA LTD

Unaudited Financial Statements

For the financial year ended 31 March 2024

Contents

DR CHOPRA LTD

STATEMENT OF FINANCIAL POSITION

As at 31 March 2024
DR CHOPRA LTD

STATEMENT OF FINANCIAL POSITION (continued)

As at 31 March 2024
Note 31.03.2024 31.03.2023
£ £
Fixed assets
Tangible assets 3 186,388 29,570
186,388 29,570
Current assets
Debtors 4 7,310 86,196
Cash at bank and in hand 71,740 0
79,050 86,196
Creditors: amounts falling due within one year 5 ( 47,325) ( 24,459)
Net current assets 31,725 61,737
Total assets less current liabilities 218,113 91,307
Creditors: amounts falling due after more than one year 6 ( 46,973) 0
Provision for liabilities 7 ( 20,105) ( 493)
Net assets 151,035 90,814
Capital and reserves
Called-up share capital 8 100 100
Profit and loss account 150,935 90,714
Total shareholders' funds 151,035 90,814

For the financial year ending 31 March 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

These financial statements have been prepared in accordance with the provisions of FRS 102 Section 1A – small entities. The financial statements of Dr Chopra Ltd (registered number: 14008998) were approved and authorised for issue by the Board of Directors on 25 March 2025. They were signed on its behalf by:

Dr Ankur Chopra
Director
DR CHOPRA LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2024
DR CHOPRA LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial period, unless otherwise stated.

General information and basis of accounting

Dr Chopra Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is Springfield Goatham Lane, Broad Oak, Rye, TN31 6EY, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The directors have assessed the Statement of Financial Position and likely future cash flows at the date of approving these financial statements. The directors have a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

Turnover is recognised when the significant risks and rewards are considered to have been transferred to the customer.

Interest income

Interest income is recognised when it is probable that the economic benefits will flow to the Company and the amount of revenue can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Taxation

Current tax
Current tax is provided at amounts expected to be paid (or recoverable) using the tax rates and laws that have been enacted or substantively enacted at the Statement of Financial Position date.

Deferred tax
Deferred tax arises as a result of including items of income and expenditure in taxation computations in periods different from those in which they are included in the Company's financial statements. Deferred tax is provided in full on timing differences which result in an obligation to pay more or less tax at a future date, at the average tax rates that are expected to apply when the timing differences reverse, based on current tax rates and laws. Deferred tax assets and liabilities are not discounted.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible fixed assets

Tangible fixed assets are stated at cost. Cost includes costs directly attributable to making the asset capable of operating as intended. Depreciation is provided on all tangible fixed assets, other than investment properties and freehold land, at rates calculated to write off the cost or valuation, less estimated residual value, of each asset on a reducing balance basis over its expected useful life, as follows:

Land and buildings 25 % reducing balance
Vehicles 5 years straight line
Tools and equipment 25 % reducing balance

Residual value represents the estimated amount which would currently be obtained from disposal of an asset, after deducting estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life.

Impairment of assets

Assets, other than those measured at fair value, are assessed for indicators of impairment at each Statement of Financial Position date. If there is objective evidence of impairment, an impairment loss is recognised in the Statement of Income and Retained Earnings as described below.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts, except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Provisions

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that the Company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the Statement of Financial Position date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Ordinary share capital

The ordinary share capital of the Company is presented as equity.

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.

2. Employees

Year ended
31.03.2024
Period from
29.03.2022 to
31.03.2023
Number Number
Monthly average number of persons employed by the Company during the year, including directors 2 2

3. Tangible assets

Land and buildings Vehicles Tools and equipment Total
£ £ £ £
Cost
At 01 April 2023 27,603 0 4,184 31,787
Additions 0 209,778 15,968 225,746
Disposals 0 ( 48,000) 0 ( 48,000)
At 31 March 2024 27,603 161,778 20,152 209,533
Accumulated depreciation
At 01 April 2023 1,725 0 492 2,217
Charge for the financial year 6,470 18,681 2,977 28,128
Disposals 0 ( 7,200) 0 ( 7,200)
At 31 March 2024 8,195 11,481 3,469 23,145
Net book value
At 31 March 2024 19,408 150,297 16,683 186,388
At 31 March 2023 25,878 0 3,692 29,570

4. Debtors

31.03.2024 31.03.2023
£ £
Trade debtors 7,310 21,505
Amounts owed by directors 0 64,691
7,310 86,196

5. Creditors: amounts falling due within one year

31.03.2024 31.03.2023
£ £
Amounts owed to directors 24,594 0
Accruals 3,538 3,300
Taxation and social security 19,193 21,159
47,325 24,459

6. Creditors: amounts falling due after more than one year

31.03.2024 31.03.2023
£ £
Obligations under finance leases and hire purchase contracts 46,973 0

There are no amounts included above in respect of which any security has been given by the small entity.

7. Deferred tax

31.03.2024 31.03.2023
£ £
At the beginning of financial year/period ( 493) 0
Charged to the Statement of Income and Retained Earnings ( 19,612) ( 493)
At the end of financial year/period ( 20,105) ( 493)

8. Called-up share capital

31.03.2024 31.03.2023
£ £
Allotted, called-up and fully-paid
100 Ordinary shares of £ 1.00 each 100 100

9. Related party transactions

Transactions with the entity's directors

31.03.2024 31.03.2023
£ £
Amounts owed to/ (by) directors 24,594 (64,691)

At 31 March 2024 the company owed the directors' £24,594.